Epigenomics' 2007 Revenues, Net Loss Decline | GenomeWeb
NEW YORK (GenomeWeb News) – Epigenomics today said that its 2007 revenues dropped 25.7 percent and its net loss fell 14.3 percent as the firm shifted its focus during the year to a strategy of non-exclusive licensing agreements intended to more rapidly commercialize molecular diagnostic products.
The Berlin, Germany-based firm reported full-year 2007 revenues of €2.6 million ($4.1 million), down from €3.5 million in 2006. Epigenomics said the decline was exclusively attributable to a terminated collaboration with Roche.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.